UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 65

Sortiert nach

Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

Blood cancer journal (New York), 2023-12, Vol.13 (1), p.181-181, Article 181

2023

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

Bone marrow transplantation (Basingstoke), 2015-01, Vol.50 (1), p.95-99

2015

Link zum Volltext

Verfügbarkeit prüfen

CyBorD induction therapy in clinical practice

Bone marrow transplantation (Basingstoke), 2015-03, Vol.50 (3), p.375-379

2015

Link zum Volltext

Verfügbarkeit prüfen

A single centre retrospective analysis of the addition of clarithromycin (biaxin) to lenalidomide and dexamethasone (len-dex) during time of progressive disease in patients with multiple myeloma (MM)

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e298-e298

2015

Link zum Volltext

Verfügbarkeit prüfen

A Retrospective Analysis at the Princess Margaret Cancer Centre of the Initial Therapy of AL Amyloidosis: CyBorD versus Other Regimens

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e196-e197

2015

Link zum Volltext

Verfügbarkeit prüfen

Expression and mutation status of candidate kinases in multiple myeloma

Leukemia, 2007-05, Vol.21 (5), p.1124-1127

2007

Link zum Volltext

Verfügbarkeit prüfen

Influence of Type II Diabetes on Arterial Tone and Endothelial Function in Murine Mesenteric Resistance Arteries

Journal of vascular research, 2001-11, Vol.38 (6), p.578-589

2001

Link zum Volltext

Verfügbarkeit prüfen

Expression and mutation status of candidate kinases in multiple myeloma

Leukemia, 2008-04, Vol.22 (4), p.889-890

2008

Link zum Volltext

Verfügbarkeit prüfen

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

Blood, 2015-12, Vol.126 (23), p.5361-5361

2015

Link zum Volltext

Verfügbarkeit prüfen

A molecular compendium of genes expressed in multiple myeloma

Blood, 2002-09, Vol.100 (6), p.2175-2186

2002

Link zum Volltext

Verfügbarkeit prüfen

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

British journal of haematology, 2004-03, Vol.124 (5), p.595-603

2004

Link zum Volltext

Verfügbarkeit prüfen

The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades

The Journal of experimental medicine, 2004-09, Vol.200 (6), p.737-747

2004

Link zum Volltext

Verfügbarkeit prüfen

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients

Blood, 2003-07, Vol.102 (2), p.772-773

2003

Link zum Volltext

Verfügbarkeit prüfen

PS1376 LENALIDOMIDE MAINTENANCE POSITIVELY IMPACTS OUTCOMES IN MULTIPLE MYELOMA WITHOUT NEGATIVE IMPACTS IN RELAPSE: AN ANALYSIS OF REAL WORLD DATA FROM THE MYELOMA CANADA RESEARCH NETWORK NATIONAL DATABASE

HemaSphere, 2019-06, Vol.3 (S1), p.629-630

2019

Link zum Volltext

Verfügbarkeit prüfen

Erratum: Expression and mutation status of candidate kinases in multiple myeloma

Leukemia, 2008-04, Vol.22 (4), p.889-890

2008

Link zum Volltext

Verfügbarkeit prüfen

A333 Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM

Clinical lymphoma & myeloma, 2009-02, Vol.9, p.S53-S53

2009

Link zum Volltext

Verfügbarkeit prüfen

A334 Bortezomib-Based Therapy Following Prior Lenalidomide + Dexamethasone in Relapsed Multiple Myeloma

Clinical lymphoma & myeloma, 2009-02, Vol.9, p.S53-S54

2009

Link zum Volltext

Verfügbarkeit prüfen

Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus

Molecular and cellular biochemistry, 2001-08, Vol.224 (1-2), p.29-37

2001

Link zum Volltext

Verfügbarkeit prüfen

Influence of type II iabetes on arterial tone and endothelial function in murine mesenteric resistance arteries

Journal of vascular research, 2001, Vol.38 (6), p.578-589

2001

Link zum Volltext

Verfügbarkeit prüfen

Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada

European journal of haematology, 2021-10, Vol.107 (4), p.416-427

2021

Link zum Volltext

Verfügbarkeit prüfen

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents

British journal of haematology, 2013-08, Vol.162 (4), p.483-488

2013

Link zum Volltext

Verfügbarkeit prüfen

Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients

Cancer medicine (Malden, MA), 2017-01, Vol.6 (1), p.3-11

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase I‐II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma

British journal of haematology, 2015-01, Vol.168 (1), p.46-54

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of thalidomide‐based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

American journal of hematology, 2013-04, Vol.88 (4), p.337-338

2013

Link zum Volltext

Verfügbarkeit prüfen

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

Biology of blood and marrow transplantation, 2012-05, Vol.18 (5), p.773-779

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 65

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(64)
Berichte
(1)

Sprache

Englisch
(65)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(18)
Hematology
(17)
Male
(13)
Adult
(12)
Aged
(12)
Middle Aged
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Multiple Myeloma - Drug Therapy
(11)
Female
(10)
Multiple Myeloma
(10)
Multiple Myeloma - Pathology
(9)
Oncology
(9)
Treatment Outcome
(9)
Multiple Myeloma - Mortality
(8)
Retrospective Studies
(8)
Aged, 80 And Over
(7)
Thalidomide - Analogs & Derivatives
(7)
Lenalidomide
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

CyBorD induction therapy in clinical practice

A single centre retrospective analysis of the addition of clarithromycin (biaxin) to lenalidomide and dexamethasone (len-dex) during time of progressive disease in patients with multiple myeloma (MM)

A Retrospective Analysis at the Princess Margaret Cancer Centre of the Initial Therapy of AL Amyloidosis: CyBorD versus Other Regimens

Expression and mutation status of candidate kinases in multiple myeloma

Influence of Type II Diabetes on Arterial Tone and Endothelial Function in Murine Mesenteric Resistance Arteries

Expression and mutation status of candidate kinases in multiple myeloma

Patterns of Relapse and Progression in Multiple Myeloma Patients Treated with Conventional and Novel Agent-Based Therapy: A Single Centre Experience

A molecular compendium of genes expressed in multiple myeloma

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

The SH3-SAM adaptor HACS1 is up-regulated in B cell activation signaling cascades

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients

PS1376 LENALIDOMIDE MAINTENANCE POSITIVELY IMPACTS OUTCOMES IN MULTIPLE MYELOMA WITHOUT NEGATIVE IMPACTS IN RELAPSE: AN ANALYSIS OF REAL WORLD DATA FROM THE MYELOMA CANADA RESEARCH NETWORK NATIONAL DATABASE

Erratum: Expression and mutation status of candidate kinases in multiple myeloma

A333 Phase I/II Trial of Cyclophosphamide, Prednisone, and Lenalidomide for Relapsed and Refractory MM

A334 Bortezomib-Based Therapy Following Prior Lenalidomide + Dexamethasone in Relapsed Multiple Myeloma

Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob/ob mouse model of non-insulin dependent diabetes mellitus

Influence of type II iabetes on arterial tone and endothelial function in murine mesenteric resistance arteries

Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada

Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents

Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients

Phase I‐II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma

Efficacy of thalidomide‐based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

Suchergebnisse filtern